Global Temporal Trends And Projections of Acute Hepatitis E Incidence Among Women of Childbearing Age: Age-Period-Cohort Analysis 2021

Journal of Infection, Год журнала: 2024, Номер 89(4), С. 106250 - 106250

Опубликована: Авг. 23, 2024

Acute hepatitis E (AHE) poses a significant threat to global public health, particularly among women of childbearing age (WCBA), who are at heightened risk for severe pregnancy-related complications. This study aimed delineate the temporal trends and project future incidence AHE in WCBA, providing insights crucial targeted prevention control strategies.

Язык: Английский

---

The effectiveness of two doses of recombinant hepatitis E vaccine in response to an outbreak in Bentiu, South Sudan: a case–control and bias indicator study

The Lancet Infectious Diseases, Год журнала: 2025, Номер unknown

Опубликована: Янв. 1, 2025

SummaryBackgroundHepatitis E virus (HEV) is a leading cause of acute viral hepatitis, particularly in Asia and Africa, where HEV genotypes 1 2 are prevalent. Although recombinant vaccine, Hecolin, available, it has not been used to control outbreaks. The licensed three-dose regimen might pose challenges for be an impactful outbreak tool. Our study aimed estimate the effectiveness two doses Hecolin context first-ever reactive use vaccine.MethodsWe conducted case–control during Bentiu internally displaced persons camp, South Sudan. Patients with jaundice syndrome (suspected cases) seeking care at Médecins Sans Frontières hospital were screened eligibility. Eligible participants those that had eligible vaccination (ie, living camp aged 16–40 years). Confirmed cases defined as individuals who tested positive hepatitis by RT-PCR or anti-HEV IgM ELISA. Each case was matched six controls age, sex, pregnancy status, residence. Self-reported status verified through cards. primary analysis two-dose vaccine effectiveness, which we estimated design using conditional logistic regression models. In secondary analyses test-negative screening method. We their bias indicator help quantify potential health behaviour biases.FindingsBetween May 10 Dec 30, 2022, identified 859 patients suspected E. Of these, 201 met eligibility criteria 21 laboratory confirmed Among cases, (48%) unvaccinated compared 33 (27%) 121 controls. unadjusted 67·8% (95% CI –28·6 91·9), 84·0% (–208·5 99·2) after adjustment confounders. suggested have more likely vaccinated than community due different health-care behaviours, potentially meaning underestimation estimates. design, uses facility-matched controls, led adjusted 89·4% (56·4 98·0).InterpretationDespite small sample size, our estimates provide evidence against genotype protracted outbreak, supporting its similar contexts.FundingMédecins Frontières.

Язык: Английский

---

Hecolin vaccination strategies for hepatitis E outbreak control in resource-constrained settings

The Lancet Infectious Diseases, Год журнала: 2025, Номер unknown

Опубликована: Янв. 1, 2025

Язык: Английский

---

Hecolin vaccine: long-term efficacy against HEV for a three-dose regimen

The Lancet, Год журнала: 2024, Номер 403(10429), С. 782 - 783

Опубликована: Фев. 19, 2024

Язык: Английский

---

Immunogenicity and Efficacy of an Accelerated Vaccination Schedule Against Hepatitis E Virus Infection in Rabbits

Journal of Medical Virology, Год журнала: 2025, Номер 97(2)

Опубликована: Фев. 1, 2025

ABSTRACT An important goal of the hepatitis E virus (HEV) vaccine is to prevent HEV in fragile, conflict‐affected, and vulnerable (FCV) settings with documented circulation, but routine vaccination schedule (0, 1, 6 months) might not provide adequate protection for them time. Therefore, this study, we aimed evaluate immunogenicity efficacy a (HEV 239 vaccine, Hecolin) using an accelerated (vaccine doses at 0 7 days). Two (0 days) induced high titers anti‐HEV protective antibodies short period time rabbits group, which could protect from infection compared group. Our results suggest that shorter The should be further recommended use as backup FCV or during outbreak.

Язык: Английский

---

Effectiveness of a hepatitis E vaccine against medically-attended symptomatic infection in HBsAg-positive adults from a test-negative design study

Nature Communications, Год журнала: 2025, Номер 16(1)

Опубликована: Фев. 17, 2025

The effectiveness of the hepatitis E vaccine in high-risk groups, such as chronic B (CHB) patients, remains understudied. A key clinical manifestation CHB is persistent positivity surface antigen (HBsAg). We conducted a test-negative design study involving 2,926 HBsAg-positive individuals (born 1941-1991; median age 49.0; male-to-female ratio 1.4), identified through surveillance system, part phase 3 trial (NCT01014845) recombinant HEV 239 (Hecolin). This system monitored suspected cases and performed diagnoses across 11 townships Dongtai, Jiangsu, China, from 2007 to 2017. Vaccine was assessed by comparing vaccination status between confirmed 96 2830 controls, using logistic regression adjusted for sex age. found that associated with reduced risk among individuals, an estimated 72.1% [95% confidence interval (CI) 11.2-91.2], 81.5% (95% CI 35.9-94.6) participants. Our findings show highly effective adults, supporting its future recommended use this population.

Язык: Английский

---

Broadly neutralizing antibodies isolated from HEV convalescents confer protective effects in human liver-chimeric mice

Nature Communications, Год журнала: 2025, Номер 16(1)

Опубликована: Фев. 26, 2025

Abstract Hepatitis E virus (HEV) causes 3.3 million symptomatic cases and 44,000 deaths per year. Chronic infections can arise in immunocompromised individuals, pregnant women may suffer from fulminant disease as a consequence of HEV infection. Despite these important implications for public health, no specific antiviral treatment has been approved to date. Here, we report combined functional, biochemical, X-ray crystallographic studies that characterize the human antibody response convalescent patients. We identified class potent broadly neutralizing antibodies (bnAbs), targeting quaternary epitope located at tip capsid protein pORF2 contains an N-glycosylation motif is conserved across members Hepeviridae . These glycan-sensitive bnAbs specifically recognize non-glycosylated present infectious particles but not secreted glycosylated form acting decoy. Our most bnAb protects liver-chimeric mice intraperitoneal challenge co-housing exposure. results provide insights into this emerging pathogen support development combat

Язык: Английский

---

Assessing the effectiveness of the varicella vaccine in primary and secondary school students in Qingdao, China: A matched case–control study

Infectious Diseases Now, Год журнала: 2025, Номер 55(3), С. 105049 - 105049

Опубликована: Фев. 27, 2025

Язык: Английский

---

Safety and immunogenicity of hepatitis E vaccine in compensated liver cirrhosis with chronic hepatitis B

Clinical Microbiology and Infection, Год журнала: 2025, Номер unknown

Опубликована: Фев. 1, 2025

Язык: Английский

---

Cost‐Effectiveness Analysis of Hepatitis E Vaccination Strategies for Swine Workers

Transboundary and Emerging Diseases, Год журнала: 2025, Номер 2025(1)

Опубликована: Янв. 1, 2025

Hepatitis E virus (HEV) is endemic in China, with swine as the most common reservoir. It poses a zoonotic public health risk to workers. This study evaluated cost‐effectiveness of hepatitis vaccination for this high‐risk group China. A decision tree‐Markov model was utilized evaluate two strategies, without or following screening, workers aged 16–60 China from societal perspectives, compared no vaccination. We calculated HEV‐related cases and deaths averted, quality‐adjusted life years (QALYs) gained, incremental ratios (ICERs) willingness‐to‐pay (WTP) threshold GDP per capita. sensitivity analysis conducted. Additionally, we stimulated scenarios fully receiving 3‐dose schedule, partially 2‐dose schedule. Both strategies significantly reduced ICERs were estimated be USD 11,428.16 9830.71/QALY averted respectively, both lower than capita (USD 12,325.24, 2023). Furthermore, one‐way identified discount rate, utility asymptomatic cases, probability symptomatic infection crucial factors affecting ICER. Probabilistic (PSA) showed 47.5% 52.5% Notably, screening cost‐ineffective after age 40 at price 138.0/dose. schedules cost‐effective, regardless while schedule strategy. would optimal Vaccination starting an earlier vaccine prices can improve cost‐effectiveness. may recommended during outbreak achieve

Язык: Английский

---